EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study

Cori L Daines, Elizabeth Tullis, Stefano Costa, Rachel W Linnemann iD, Marcus A Mall iD, Edward F McKone, Deepika Polineni, Bradley S Quon, Felix C Ringshausen iD, Steven M Rowe, Hiran Selvadurai, Jennifer L Taylor-Cousar iD und 12 weitere

European Respiratory Journal · 2023-12 · 62 (6) · 2202029

DOI: 10.1183/13993003.02029-2022 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Respiratory Journal, online erschienen am 09.11.2023. Verfasst von Cori L Daines und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Arizona, Banner University Medical Center, Tucson, AZ, USA cdaines@arizona.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Vertex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least one F508del allele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients.

Methods

In this phase 3, open-label, single-arm extension study, participants with F508del –minimal function (from a 24-week parent study; n=399) or F508del – F508del (from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit.

Results

At the Week 144 interim analysis, mean duration of exposure to ELX/TEZ/IVA in the extension study was 151.1 weeks. Exposure-adjusted rates of adverse events (AEs) (586.6 events per 100 participant-years) and serious AEs (22.4 events per 100 participant-years) were lower than in the ELX/TEZ/IVA treatment group in the 24-week parent study (1096.0 and 36.9 events per 100 participant-years, respectively); most participants had AEs classified as mild (16.4% of participants) or moderate (60.3% of participants) in severity. 14 participants (2.8%) had AEs that led to treatment discontinuation. Following initiation of ELX/TEZ/IVA, participants had increases in forced expiratory volume in 1 s (FEV 1 ) percentage predicted, Cystic Fibrosis Questionnaire-Revised respiratory domain score and body mass index, and had decreases in sweat chloride concentration and pulmonary exacerbation rates that were maintained over the interim analysis period. The mean annualised rate of change in FEV 1 % pred was +0.07 (95% CI −0.12–0.26) percentage points among the participants.

Conclusions

ELX/TEZ/IVA was generally safe and well tolerated, with a safety profile consistent with the 24-week parent study. Participants had sustained improvements in lung function, respiratory symptoms, CF transmembrane conductance regulator function, pulmonary exacerbation rates and nutritional status. These results support the favourable safety profile and durable, disease-modifying clinical benefits of ELX/TEZ/IVA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansAllelesCystic Fibrosis Transmembrane Conductance RegulatorMutationPyrazolesPyridinesPyrrolidinesAminophenolsQuinolonesIndolesBenzodioxoles

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorelexacaftorPyrazolesPyridinesPyrrolidinesivacaftorAminophenolsQuinolonestezacaftorIndoles

Autor:innen und Institutionen

  • University of Arizona, Banner University Medical Center, Tucson, AZ, USA cdaines@arizona.edu.
  • C.L. Daines and E. Tullis contributed equally to this work.
  • St Michael's Hospital, Toronto, ON, Canada.
  • University of Messina, Messina, Italy.
  • Emory University, Atlanta, GA, USA.
  • Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Rachel W Linnemann, Marcus A Mall, Felix C Ringshausen, Jennifer L Taylor-Cousar, Matthias Griese

Förderung

  • NIDDK NIH HHS
  • Vertex Pharmaceuticals

Zitieren

APA

Daines, C. L., Tullis, E., Costa, S., Linnemann, R. W., Mall, M. A., McKone, E. F., Polineni, D., Quon, B. S., Ringshausen, F. C., Rowe, S. M., Selvadurai, H., Taylor-Cousar, J. L., Withers, N. J., Ahluwalia, N., Moskowitz, S. M., Prieto-Centurion, V., Tan, Y. V., Tian, S., Weinstock, T., …, & VX17-445-105 Study Group (2023). Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. European Respiratory Journal, 62(6), 2202029. https://doi.org/10.1183/13993003.02029-2022

Vancouver

Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, et al. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. European Respiratory Journal. 2023;62(6):2202029. doi:10.1183/13993003.02029-2022

BibTeX
@article{Daines2023,
  author = {Daines, Cori L and Tullis, Elizabeth and Costa, Stefano and Linnemann, Rachel W and Mall, Marcus A and McKone, Edward F and Polineni, Deepika and Quon, Bradley S and Ringshausen, Felix C and Rowe, Steven M and Selvadurai, Hiran and Taylor-Cousar, Jennifer L and Withers, Nicholas J and Ahluwalia, Neil and Moskowitz, Samuel M and Prieto-Centurion, Valentin and Tan, Yaoyuan Vincent and Tian, Simon and Weinstock, Tanya and Xuan, Fengjuan and Zhang, Yaohua and Ramsey, Bonnie and Griese, Matthias and VX17-445-105 Study Group, VX17-445-105 Study Group},
  title = {Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {6},
  pages = {2202029},
  doi = {10.1183/13993003.02029-2022}
}
Kostenlos starten →